Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Identifieur interne : 000529 ( PascalFrancis/Checkpoint ); précédent : 000528; suivant : 000530Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Auteurs : P. Hadji [Allemagne] ; M. Ziller [Allemagne] ; D. G. Kieback [Allemagne] ; W. Dornoff [Allemagne] ; H. W. Tessen [Allemagne] ; T. Menschik [France] ; J. Kuck [Allemagne] ; F. Melchert [Allemagne] ; A. Hasenburg [Allemagne]Source :
- Annals of oncology [ 0923-7534 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Allemagne.
- topic : Prospective.
English descriptors
- KwdEn :
Abstract
Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
Affiliations:
- Allemagne, France
- Bade-Wurtemberg, Berlin, District de Fribourg-en-Brisgau, District de Giessen, District de Karlsruhe, Hesse (Land), Île-de-France
- Berlin, Fribourg-en-Brisgau, Mannheim, Marbourg, Paris
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0309205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title><author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Helios Kliniken</s1><s2>Aue</s2><s3>DEU</s3><sZ>3 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Aue</wicri:noRegion><wicri:noRegion>Helios Kliniken</wicri:noRegion><wicri:noRegion>Helios Kliniken</wicri:noRegion></affiliation></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1><s2>Trier</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion><wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion></affiliation></author><author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1><s2>Goslar</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Goslar</wicri:noRegion><wicri:noRegion>Onkologische Schwerpunktpraxis</wicri:noRegion><wicri:noRegion>Onkologische Schwerpunktpraxis</wicri:noRegion></affiliation></author><author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1><s2>Berlin</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>University of Mannheim</s1><s2>Mannheim</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1><s2>Freiburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0309205</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0309205 INIST</idno><idno type="RBID">Pascal:09-0309205</idno><idno type="wicri:Area/PascalFrancis/Corpus">000674</idno><idno type="wicri:Area/PascalFrancis/Curation">000732</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000529</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000529</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title><author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Helios Kliniken</s1><s2>Aue</s2><s3>DEU</s3><sZ>3 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Aue</wicri:noRegion><wicri:noRegion>Helios Kliniken</wicri:noRegion><wicri:noRegion>Helios Kliniken</wicri:noRegion></affiliation></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1><s2>Trier</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion><wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion></affiliation></author><author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1><s2>Goslar</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Goslar</wicri:noRegion><wicri:noRegion>Onkologische Schwerpunktpraxis</wicri:noRegion><wicri:noRegion>Onkologische Schwerpunktpraxis</wicri:noRegion></affiliation></author><author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1><s2>Berlin</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>University of Mannheim</s1><s2>Mannheim</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1><s2>Freiburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Aromatase inhibitor</term><term>Bone</term><term>Bone mineral density</term><term>Breast cancer</term><term>Clinical trial</term><term>Early</term><term>Exemestane</term><term>Fracture</term><term>Germany</term><term>Health</term><term>Osteoporosis</term><term>Prospective</term><term>Randomization</term><term>Tamoxifene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Exémestane</term><term>Tamoxifène</term><term>Os</term><term>Santé</term><term>Essai clinique</term><term>Allemagne</term><term>Prospective</term><term>Randomisation</term><term>Inhibiteur de l'aromatase</term><term>Densité minérale osseuse</term><term>Précoce</term><term>Cancer du sein</term><term>Fracture</term><term>Ostéoporose</term><term>Anticancéreux</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0></fA01><fA03 i2="1"><s0>Ann. oncol.</s0></fA03><fA05><s2>20</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</s1></fA08><fA11 i1="01" i2="1"><s1>HADJI (P.)</s1></fA11><fA11 i1="02" i2="1"><s1>ZILLER (M.)</s1></fA11><fA11 i1="03" i2="1"><s1>KIEBACK (D. G.)</s1></fA11><fA11 i1="04" i2="1"><s1>DORNOFF (W.)</s1></fA11><fA11 i1="05" i2="1"><s1>TESSEN (H. W.)</s1></fA11><fA11 i1="06" i2="1"><s1>MENSCHIK (T.)</s1></fA11><fA11 i1="07" i2="1"><s1>KUCK (J.)</s1></fA11><fA11 i1="08" i2="1"><s1>MELCHERT (F.)</s1></fA11><fA11 i1="09" i2="1"><s1>HASENBURG (A.)</s1></fA11><fA14 i1="01"><s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA14 i1="02"><s1>Helios Kliniken</s1><s2>Aue</s2><s3>DEU</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1><s2>Trier</s2><s3>DEU</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Onkologische Schwerpunktpraxis</s1><s2>Goslar</s2><s3>DEU</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Pfizer, Specialty Brand Team Europe</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Independent Clinical Research Consulting, Bölschestrasse</s1><s2>Berlin</s2><s3>DEU</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>University of Mannheim</s1><s2>Mannheim</s2><s3>DEU</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Freiburg University, Frauenklinik</s1><s2>Freiburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></fA14><fA20><s1>1203-1209</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>22429</s2><s5>354000187188000090</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>30 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0309205</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of oncology</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02R</s0></fC02><fC02 i1="02" i2="X"><s0>002B20E02</s0></fC02><fC02 i1="03" i2="X"><s0>002B15A</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Exémestane</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Exemestane</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Exemestano</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Tamoxifène</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Tamoxifene</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tamoxifeno</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Os</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Bone</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hueso</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Santé</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Health</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Salud</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Allemagne</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Germany</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Alemania</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Prospective</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Prospective</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Prospectiva</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Randomisation</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Randomization</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Aleatorización</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur de l'aromatase</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Aromatase inhibitor</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor aromatase</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Densité minérale osseuse</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Bone mineral density</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Masa mineral ósea</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Précoce</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Early</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Precoz</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Cancer du sein</s0><s2>NM</s2><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Breast cancer</s0><s2>NM</s2><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Cáncer del pecho</s0><s2>NM</s2><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Fracture</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Fracture</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Fractura</s0><s5>13</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Ostéoporose</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Osteoporosis</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Osteoporosis</s0><s5>14</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>23</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>23</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>23</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Dérivé de l'androstane</s0><s2>FR</s2><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Androstane derivatives</s0><s2>FR</s2><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Androstano derivado</s0><s2>FR</s2><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Estrogen synthase</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Estrogen synthase</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Estrogen synthase</s0><s2>FE</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Stéroïde</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Steroid</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Esteroide</s0><s5>40</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Antihormone</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Antihormone</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Antihormona</s0><s5>41</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Antioestrogène</s0><s5>42</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Antiestrogen</s0><s5>42</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Antiestrógeno</s0><s5>42</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Composé non stéroïde</s0><s5>43</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Non steroid compound</s0><s5>43</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Compuesto no esteroide</s0><s5>43</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Modulateur sélectif des récepteurs aux oestrogènes</s0><s5>44</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Selective estrogen receptor modulator</s0><s5>44</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Modulador selectivo del receptor de estrógeno</s0><s5>44</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Système ostéoarticulaire</s0><s5>45</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Osteoarticular system</s0><s5>45</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Sistema osteoarticular</s0><s5>45</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>46</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>46</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>46</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="14" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0><s2>NM</s2><s5>47</s5></fC07><fC07 i1="14" i2="X" l="ENG"><s0>Mammary gland diseases</s0><s2>NM</s2><s5>47</s5></fC07><fC07 i1="14" i2="X" l="SPA"><s0>Glándula mamaria patología</s0><s2>NM</s2><s5>47</s5></fC07><fC07 i1="15" i2="X" l="FRE"><s0>Pathologie du sein</s0><s2>NM</s2><s5>48</s5></fC07><fC07 i1="15" i2="X" l="ENG"><s0>Breast disease</s0><s2>NM</s2><s5>48</s5></fC07><fC07 i1="15" i2="X" l="SPA"><s0>Seno patología</s0><s2>NM</s2><s5>48</s5></fC07><fC07 i1="16" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0><s5>49</s5></fC07><fC07 i1="16" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0><s5>49</s5></fC07><fC07 i1="16" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0><s5>49</s5></fC07><fC07 i1="17" i2="X" l="FRE"><s0>Traumatisme</s0><s5>50</s5></fC07><fC07 i1="17" i2="X" l="ENG"><s0>Trauma</s0><s5>50</s5></fC07><fC07 i1="17" i2="X" l="SPA"><s0>Traumatismo</s0><s5>50</s5></fC07><fN21><s1>222</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>France</li></country><region><li>Bade-Wurtemberg</li><li>Berlin</li><li>District de Fribourg-en-Brisgau</li><li>District de Giessen</li><li>District de Karlsruhe</li><li>Hesse (Land)</li><li>Île-de-France</li></region><settlement><li>Berlin</li><li>Fribourg-en-Brisgau</li><li>Mannheim</li><li>Marbourg</li><li>Paris</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name></region><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name></country><country name="France"><region name="Île-de-France"><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000529 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000529 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0309205
|texte= Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
}}
| This area was generated with Dilib version V0.6.31. |  |